These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 25981231)

  • 1. Levodopa alone compared with levodopa-sparing therapy as initial treatment for Parkinson's disease: a meta-analysis.
    Xie CL; Zhang YY; Wang XD; Chen J; Chen YH; Pa JL; Lin SY; Lin HZ; Wang WW
    Neurol Sci; 2015 Aug; 36(8):1319-29. PubMed ID: 25981231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications.
    Stowe R; Ives N; Clarke CE; Deane K; ; Wheatley K; Gray R; Handley K; Furmston A
    Cochrane Database Syst Rev; 2010 Jul; (7):CD007166. PubMed ID: 20614454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial.
    ; Gray R; Ives N; Rick C; Patel S; Gray A; Jenkinson C; McIntosh E; Wheatley K; Williams A; Clarke CE
    Lancet; 2014 Sep; 384(9949):1196-205. PubMed ID: 24928805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
    Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacologic treatment of advanced Parkinson's disease: a meta-analysis of COMT inhibitors and MAO-B inhibitors.
    Talati R; Reinhart K; Baker W; White CM; Coleman CI
    Parkinsonism Relat Disord; 2009 Aug; 15(7):500-5. PubMed ID: 19167259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients.
    Kumar R; Hauser RA; Mostillo J; Dronamraju N; Graf A; Merschhemke M; Kenney C
    Int J Neurosci; 2016; 126(1):20-4. PubMed ID: 24007304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoamine oxidase B inhibitors for early Parkinson's disease.
    Macleod AD; Counsell CE; Ives N; Stowe R
    Cochrane Database Syst Rev; 2005 Jul; 2005(3):CD004898. PubMed ID: 16034956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment strategies in Parkinson's disease after a quarter century experiences with L-DOPA therapy.
    Fischer PA
    J Neural Transm Suppl; 1995; 46():381-9. PubMed ID: 8821073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease.
    Warren Olanow C; Kieburtz K; Rascol O; Poewe W; Schapira AH; Emre M; Nissinen H; Leinonen M; Stocchi F;
    Mov Disord; 2013 Jul; 28(8):1064-71. PubMed ID: 23630119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness of Dopamine Agonists and Monoamine Oxidase B Inhibitors in Early Parkinson's Disease.
    McIntosh E; Kent S; Gray A; Clarke CE; Williams A; Jenkinson C; Ives N; Patel S; Rick C; Wheatley K; Gray R;
    Mov Disord; 2021 Sep; 36(9):2136-2143. PubMed ID: 33960511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease.
    Caslake R; Macleod A; Ives N; Stowe R; Counsell C
    Cochrane Database Syst Rev; 2009 Oct; (4):CD006661. PubMed ID: 19821381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levodopa in the early treatment of Parkinson's disease.
    Murata M
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overall Efficacy and Safety of Safinamide in Parkinson's Disease: A Systematic Review and a Meta-analysis.
    Giossi R; Carrara F; Mazzari M; Lo Re F; Senatore M; Schicchi A; Corrù F; Fittipaldo VA; Pani A; Tramacere I; Elia AE; Scaglione F
    Clin Drug Investig; 2021 Apr; 41(4):321-339. PubMed ID: 33674954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors and safe dosage of levodopa for wearing-off phenomenon in Chinese patients with Parkinson's disease.
    Chen H; Fang J; Li F; Gao L; Feng T
    Neurol Sci; 2015 Jul; 36(7):1217-23. PubMed ID: 25616444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr.
    Lees AJ; Tolosa E; Olanow CW
    Mov Disord; 2015 Jan; 30(1):19-36. PubMed ID: 25488030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect and safety of levodopa alone versus levodopa sparing therapy for early Parkinson's disease: a systematic review and meta-analysis.
    Zhao YT; Liu L; Zhao Y; Xie ZY
    J Neurol; 2022 Apr; 269(4):1834-1850. PubMed ID: 34652505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
    Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C
    Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of the pharmacist in the effective management of wearing-off in Parkinson's disease.
    Simonson W; Hauser RA; Schapira AH
    Ann Pharmacother; 2007 Nov; 41(11):1842-9. PubMed ID: 17878397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.